Back to results
US 12,599,586 B2Granted
Edaravone suspension for oral administration
AssigneeK.K. Bcj-94
InventorsTetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
Life of this patent
Estimating the term…
Abstract
An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
Claims20
An edaravone suspension for human oral administration, comprising:
- water;
- edaravone particles comprising edaravone and dispersed in the water;
- and
- a dispersant dispersing the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water,
- wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm, the water and the dispersant, and the edaravone particles have a dissolution rate of 80% of more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.
2 more elements
A kit for an edaravone suspension for human oral administration, comprising:
- edaravone particles having a D50 particle size in a range of 10 μm to 50 μm and a D90 particle size in a range of 50 μm to 200 μm;
- and
- a dispersant that dissolves in water and disperses the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water,
- wherein the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.
1 more element
Dependencies are inferred from the claim text.